Inhibitory Effect Of Low-doe Paclitaxel Combined With Recombinant Human Endostatin On Breast Cancer MCF-7Cell Line

Objective: To observe the low-dose (40μg/ml) paclitaxel (PTX)combined with recombinant human endostatin (Rh-ES) in inhibitting growthof human breast cancer MCF-7cell line and suppressing the vascularendothelial growth factor (VEGF).Methods: The MCF-7cells which were in logarithmic growth phasewere divided into four groups randomly: control group (group A), groupPTX (group B), group Rh-ES (group C) and group PTX+Rh-ES (group D).The surviving MCF-7cells which were treated with the four methods wereenumerated after24h by cell counting plate counting method. Inhibitoryrates of cells of the four groups were calculated. The level of VEGF proteinand mRNA expressions of cells were detected by immunocytochemistrySABC method and RT-PCR.Result: The cell’s inhibitory rates of group PTX, Rh-ES and PTX+Rh-ES were69.17%,27.71%,and77.03%respectively. The inhibitory rate ofgroup PTX+Rh-ES was higher than that of group Rh-ES (P＝0.002), butthere was no statistic significance of inhibitory rate between group PTX+ Rh-ES and group PTX (P＝0.57). When VEGF protein and mRNAexpressions were compared between each group, those in group PTX+Rh-ES were significantly lower than in the other three groups (P<0.05). Theinhibitory rate of MCF-7cells and the expression of VEGF were in linearcorrelation (r＝0.564，P<0.001).Conclusion: Low-dose PTX combined with Rh-ES can obviouslysuppress the MCF-7cells expression of VEGF, it demonstrate the combinedmedication has synergistic effects in inhibiting tumor angiogenesis.But it isnot confirmed that has synergistic effects in inhibit the growth of MCF-7cells.